Sanofi’s profits to dip as its dengue vaccine faces dire criticism
Date: 2017-11-30   Author: Dhananjay Punekar  Category: #news

In a turning tide of the events, the use of Sanofi’s new vaccine for dengue has been severely restricted, owing to the evidence that it can lead to further deterioration in patients who have not been infected with the ailment before. The chief officials of Sanofi are expected to make suggestions to the national regulatory authorities in France that the vaccination should not be prescribed for patients who have no history of being infected by dengue.

As per medical experts, results obtained from the clinical tests performed on the patients a few years earlier depicted that the Dengvaxia vaccine offered a constant shield against dengue to those patients who were earlier affected due to the ailment. However, later on, it was found that people who were not afflicted by the virus suffered much more post the vaccination.

Initially, the firm had predicted bright growth prospects for its dengue vaccine, projecting that it would accrue a revenue of nearly EUR 1 billion per year from its sales. But, as per the estimates its sales in 2016 were assessed at EUR 55 million, much below expectations. A reliable research group has forecast that the yearly sales of Dengvaxia vaccine will reach EUR 360 million by 2022.  Sources have claimed that dengue infects millions across the globe and nearly 20,000 persons lose their lives due to the disease each year.

Though Sanofi’s Dengvaxia is the first approved vaccine of its kind, research has already depicted the limitations of vaccination through mixed results obtained from the data of clinical tests conducted on four dissimilar kinds of virus. It is anticipated that the business rivals of the firm such as Takeda Pharmaceutical are also developing an improved version of a vaccine against dengue, which can significantly impact Sanofi’s market position over the coming years.



About Author


Dhananjay Punekar

Dhananjay Punekar

Dhananjay currently works as a content writer at AlgosOnline. A post graduate in mathematics as well as business administration, he worked as a process executive in Infosys BPO Limited before switching his professional genre. Following his childhood passion, he opted fo...

Read More

More from Dhananjay


Post Recommendents

Red Dot Power plans to build 50 EV charging stations by 2019
Author: Ojaswita Kutepatil

Red Dot Power, the Singapore-based electricity retailer has recently announced that it will be investing around SGD 500,000 to install 50 electric vehicles charging stations in the nation by 2019. Reportedly, the firm wo...


Greencoat Renewables to purchase yet another wind farm in Ireland
Author: Dhananjay Punekar

Greencoat Renewables PLC, an Ireland based renewable-infrastructure firm, has decided to acquire Lisdowney, a 9.2 MW wind farm based in Co Kilkenny, for EUR 22.5 million. According to the

Nokia to opt between a sale or shut-down for its digital health unit
Author: Dhananjay Punekar

In a major turn of events witnessed across the digital health industry, Nokia has declared to have begun evaluating various alternatives for its online health activities. The firm’s decision apparently comes as a...